Changes in the quality of Chinese universities has allowed the biotechnology sector to grow
Nov 1, 2007
By:
Eric S. Langer, Eliza Yibing Zhou
Biotechnology is definitely a hot topic in China—the country's administrators recently identified it as a "cornerstone of China's national economy by 2020." But most realize that getting there will require a better trained, specialized workforce than currently exists. The Chinese government has been pumping money into life sciences education as part of its plan to achieve a global biotechnological presence over the next 15 years.
|
China's services sector is expanding to meet the needs of its biopharmaceutical industry
Jul 1, 2007
By:
Eric Langer, Eliza Yibing Zhou
Most Chinese biopharmaceuticals are relatively small and there are not enough of them to sustain a robust services sector.
|
Improvements in China's regulatory and technology scenario are creating an optimistic outlook for its vaccine industry
Apr 1, 2007
By:
Eliza Yibing Zhou
The Chinese vaccine market competition is now transferring from the former price-competition model to a technology- competition model.
|
Now that China has opened its window to the world, its biopharmaceutical industry will see more opportunities
Mar 1, 2007
By:
Eliza Yibing Zhou
The Chinese government's investments in the biopharmaceutical sector may help it become one of the leading industries in China by 2020.
|
The country strives to modernize its distribution logistics as thousands of small companies compete for profits
Feb 1, 2007
By:
Eliza Yibing Zhou
China today represents a $15-billion market for pharmaceutical products. China's pharmaceutical industry has been expanding at about 20% over the past five years. It has been predicted that China will become the world's fifth largest single pharmaceutical market by 2010. With such a fast-growing market segment and a huge population, simply getting pharmaceuticals to the patients and healthcare providers is becoming a daunting task. Biopharmaceuticals distributers face the same challenge, with the added complications associated with cold-chain management, shelf-life, and product stability.
|
A relatively liberal regulatory environment and huge market potential are leading to rapid industry expansion
Jan 1, 2007
By:
Eliza Yibing Zhou, Eric S. Langer
China is home to more than 400 biogeneric manufacturers, which develop generic biopharmaceuticals for the domestic population.
|
|
